CEAPRO INC - CRPOF STOCK NEWS

Ceapro Inc. (OTCQX: CRPOF) announced that its abstract titled "Reprogramming Rogue Macrophages: Yeast Beta-Glucan Microparticles as a Macrophage Modulator for Lung Fibrosis" has been accepted for presentation at the American Thoracic Society International Conference in Washington, DC from May 19-24, 2023. This presentation will showcase findings from a collaboration with McMaster University researchers that investigate the anti-fibrotic properties of Ceapro's yeast beta glucan. The research aims to explore its potential as an inhalable treatment for lung fibrotic diseases.

Ceapro Inc. (OTCQX: CRPOF) announced its abstract titled Application of Avena Sativa Derived Therapeutics β-Glucan and Avenanthramide Accelerate Wound Healing in Mice Via Angiogenic and Anti-inflammatory Mechanisms will be presented at the Annual Meeting of the Wound Healing Society (WHS) from April 26-29, 2023. The research collaboration with The Angiogenesis Foundation showcases the efficacy of oat-based bioactives in reducing scar formation and stimulating wound healing. This presentation emphasizes Ceapro's commitment to advancing healthcare and cosmetic applications of its bioactive products, highlighting their potential in tissue regeneration and inflammation reduction.

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF), a Canadian biotechnology company, will host a live video webcast on January 18, 2023, at 3:00 PM ET. CEO Gilles Gagnon will present at the Virtual Investor 2023 Companies to Watch Event. This event aims to highlight Ceapro's innovative extraction technology and its applications in healthcare and cosmetic industries. The webcast will be accessible on the Company's website, with a replay available for 90 days.

Ceapro specializes in producing active ingredients from oats and renewable plant resources.

Ceapro announced the granting of stock options to employees, officers, and directors totaling 740,000 common shares at an exercise price of $0.62. The options will vest in three equal installments over two years, with the first installment vesting immediately. Each option is exercisable for five years from the grant date and is subject to TSX Venture approval. This move aims to incentivize key personnel and aligns their interests with company performance.

Ceapro Inc. has received Health Canada approval for its Phase 1/2a clinical study to evaluate a pharmaceutical grade tablet of avenanthramide, aiming to establish its safety and efficacy as a potential anti-inflammatory product. Conducted in collaboration with the Montreal Heart Institute, the trial is set to recruit up to 96 subjects, exploring the effects of varying dosages. It seeks initial data on its activity against cardiovascular and inflammatory diseases, such as atherosclerosis and COVID-19-related conditions. This development is seen as a significant step towards expanding Ceapro's biopharmaceutical business model.

Ceapro Inc. (OTCQX: CRPOF) reported its Q3 2022 financial results, revealing sales of $3,845,000, a decline from $4,523,000 in Q3 2021. Year-to-date sales increased by 14%, totaling $15,517,000 compared to $13,633,000 in 2021. Income before tax rose to $1,128,000 from $875,000, while year-to-date income surged 186% to $5,919,000. R&D investments decreased to $314,000 from $1,403,000. The company is advancing its Avenanthramides clinical trials and enhancing its product portfolio, benefiting from a strong cash flow of $5,644,000 generated in the first nine months.

Ceapro (CRPOF) has signed a license agreement with the University of Alberta to install its PGX processing unit at the Agri-Food Discovery Place (AFDP). This move aims to scale up the PGX technology to enhance the bioavailability of active ingredients like Coenzyme Q10. The company plans to increase capacity by 5 to 10 times compared to its current facility. Initial bioactives to be processed include alginate and yeast beta-glucan, which have potential applications in nutraceuticals and pharmaceuticals. This development is expected to facilitate collaborations with commercial partners for innovative product formulations.

Ceapro (CRPOF) announced positive results from its study on PGX-processed carriers for CoQ10 delivery, demonstrating superior bioavailability. Conducted with the University of Alberta, the study showed that certain formulations increased CoQ10 absorption significantly, achieving up to 3-fold improvement compared to standard formulations. The findings support advancing Ceapro's PGX Technology, aimed at developing first-in-class slow-release products. CEO Gilles Gagnon highlighted the potential for innovative delivery systems in various markets, reinforcing the company's growth strategy and investment decisions for the next phase.